Parikh RC, DeMartino JK, Krishnarajah G, Hitchens A, Bello F, Meyers J, Levin M. Respiratory syncytial virus–attributable hospitalizations among adults ≥60 years in the United States – a comparison by race/ethnicity. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Parikh RC, DeMartino JK, Krishnarajah G, Hitchens A, Bello F, Meyers J, Levin M. Respiratory syncytial virus versus influenza hospitalizations among adults ≥60 years in the United States. Poster presented at the 2023 Respiratory Synctial Virus Foundation (RSVVW); February 22, 2023. Lisbon, Portugal.
Poirrier JE, DeMartino JK, Nagar S, Carrico J, Hicks K, Meyers J, Stoddard J. Burden of opioid use for pain management among adult herpes zoster patients in the US and the potential impact of vaccination. Hum Vaccin Immunother. 2022 Nov;18(5):2040328. doi: 10.1080/21645515.2022.2040328
Poirrier JE, Meyers JL, Nagar SP, Patterson BJ, Glasser LI, Jabbour SA. Herpes zoster incidence and burden in adults with type 2 diabetes in the U.S.: a retrospective database analysis. Diabetes Care. 2022 Nov 1;45(11):2585-93. doi: 10.2337/dc21-2053
Poirrier J-E, Carrico J, DeMartino JK, Hicks KA, Stoddard JJ, Nagar S, Meyers J. The potential for reducing opioid and analgesic prescriptions via herpes zoster vaccination. Poster presented at the IDWeek 2020 Virtual Conference; October 21, 2020.
Poirrier J-E, Nagar S, Meyers J, Glasser L, Jabbour S. Incidence of herpes zoster in patients with type 2 diabetes and consequences for treatment. Poster presented at the 2020 American Diabetes Association 80th Virtual Scientific Sessions; June 13, 2020. Chicago, IL.
Carreno JJ, Tam IM, Meyers JL, Esterberg E, Candrilli SD, Lodise TP. Longitudinal, nationwide, cohort study to assess incidence, outcomes, and costs associated with complicated urinary tract infection. Open Forum Infect Dis. 2019 Nov;6(11):ofz446. doi: 10.1093/ofid/ofz446
Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson BJ, Levin MJ. Costs of herpes zoster complications in older adults: a cohort study of US claims database. Vaccine. 2019 Feb 21;37(9):1235-44. doi: 10.1016/j.vaccine.2018.11.079
Meyers JL, Candrilli SD, Rausch DA, Yan S, Patterson B, Levin M. Cost of herpes zoster and herpes zoster-related complications among immunocompromised individuals. Vaccine. 2018 Oct 29;36(45):6810-8. doi: 10.1016/j.vaccine.2018.08.080
Sinha A, Meyers J, Samant S, Trantham L, Candrilli S. The incremental burden of congenital cytomegalovirus in the first year of life: a retrospective case-control analysis of Medicaid and commercial claims data. Presented at the 2018 CMV Public Health and Policy Conference; September 25, 2018. Burlington, VT.
Rausch D, Levin MJ, Meyers JL, Candrilli SD, Yan S, Krishnarajah G, Patterson B. Cost of herpes zoster and related complications in patients with immunocompromising conditions aged ≥50 years: a US insurance claims data analysis. Presented at the AAFP Family Medicine Experience; September 2017. San Antonio, TX.
Rausch DA, Levin M, Meyers J, Candrilli S, Yan S, Krishnarajah G, Patterson B. Cost of diagnosed herpes zoster complications in patients age ≥50 years: a US claims data analysis. Poster presented at the IAGG 2017 World Congress; July 23, 2017. San Francisco, CA. [abstract] Innov Aging. 2017 Jul; 1(Suppl 1):902. doi: 10.1093/geroni/igx004.3234
Buck PO, Meyers JL, Gordon LD, Parikh R, Kurosky SK, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017 Jul;145(10):2109-21. doi: 10.1017/S0950268817000887.
Buck PO, Gordon LD, Meyers J, Parikh R, Kurosky S, Davis KL. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease: a US database study. Poster presented at the National Foundation for Infectious Diseases 19th Annual Conference on Vaccine Research; April 2016. Bethesda, MD.
Cohen CJ, Meyers JL, Davis KL. Association between daily antiretroviral pill burden and treatment adherence, hospitalisation risk, and other healthcare utilisation and costs in a US medicaid population with HIV. BMJ Open. 2013 Aug 1;3(8):e003028.
Cohen C, Davis KL, Meyers JL. Association of partial adherence (PA) to antiretroviral therapy with hospitalizations and healthcare costs in an HIV population. Poster presented at the 11th International Congress on Drug Therapy in HIV Infection; November 2012.
Cohen C, Davis KL, Meyers JL. Effect of daily antiretroviral pill burden on hospitalizations in United States medicaid enrollees with HIV: an analysis of hospital characteristics and costs. Poster presented at the 24th Annual Meeting of the Academy of Managed Care Pharmacy; April 2012.
Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured hiv patients in the United States. PLoS One. 2012 Feb 24;7(2):e31591.
Cohen C, Davis KL, Meyers JL. Effect of daily antiretroviral pill burden on health care utilization and costs in United States Medicaid enrollees with HIV. Poster presented at the 13th European AIDS Conference; October 2011.
Cohen C, Davis KL, Meyers JL. Association between daily antiretroviral pill burden and hospitalization risk in a Medicaid population with HIV. Poster presented at the 51st Interscience Conference on Antimicrobial Agents and Chemotherapy; September 2011.
Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, Danna RP, Papadopoulos G. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011 May 1;39(4):e15-20.
Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral therapy and the associated risk of hospitalization among commercially insured HIV patients in the United States. Poster presented at the 23rd Annual Meeting and Showcase of the Academy of Managed Care Pharmacies; April 2011.
Menzin J, Marton JP, Meyers JL, Carson RT, Rothermel CD, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections because of Staphylococcus aureus. Am J Infect Control. 2010 Feb;38(1):44-9. doi: 10.1016/j.ajic.2009.04.287.
Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, Papadopoulos G. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high risk patients. Am J Health Syst Pharm. 2009 Oct;66(19):1711-7. doi: 10.2146/ajhp080325.
Marton JP, Jackel JL, Carson RT, Rothermel CD, Friedman M, Menzin J. Costs of skin and skin structure infections due to Staphylococcus aureus: an analysis of managed-care claims. Curr Med Res Opin. 2008 Oct;24(10):2821-8.
Menzin J, Marton J, Jackel J, Carson R, Rothermel C, Friedman M. Inpatient treatment patterns, outcomes, and costs of skin and skin structure infections due to staphylococcus aureus. Poster presented at the 20th Annual Meeting and Showcase of the Academy of Managed Care Pharmacy; April 2008.
Marton J, Jackel J, Carson R, Rothermel C, Menzin J. Predictors of costs for skin and skin structure infections due to staphylococcus aureus using a managed-care perspective. Poster presented at the 2007 ISPOR 10th Annual European Congress; October 2007. Dublin, Ireland. [abstract] Value Health. 2007 Nov; 10(6):A446.
Menzin J, Jackel J, Friedman M, Perfect J, Langston A, Danna R, Papadopoulos G. Clinical and economic burden of invasive fungal infections among hospitalized patients: findings from a U.S. national database. O-1869. Poster presented at the 47th Intersciences Conference on Antimicrobial Agents and Chemotherapy Meeting of the American Society for Microbiology; September 2007.